<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRIZIVIRÂ - abacavir sulfate, lamivudine and zidovudineÂ tablet, film coatedÂ </strong><br>State of Florida DOH Central Pharmacy<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TRIZIVIR safely and effectively. See full prescribing information for TRIZIVIR.<br>Â <br>TRIZIVIR (abacavir sulfate, lamivudine, and zidovudine) Tablets, for oral use<br>Initial U.S. Approval: 2000</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, HEMATOLOGIC TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span>, EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been associated with abacavir-containing products. (5.1)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir is a multi-organ clinical syndrome. (5.1)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Patients who carry the HLA-B*5701 allele are at high risk for experiencing a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir. (5.1)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Discontinue TRIZIVIR as soon as a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected. Regardless of HLA-B*5701 status, permanently discontinue TRIZIVIR if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out. (5.1)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, NEVER restart TRIZIVIR or any other abacavir-containing product. (5.1)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Hematologic toxicity, including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, has been associated with the use of zidovudine, a component of TRIZIVIR. (5.2)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with prolonged use of zidovudine. (5.3)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. (5.4)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) and have discontinued lamivudine, a component of TRIZIVIR. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B treatment. (5.5)</span></dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, HEMATOLOGIC TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span>, EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been associated with abacavir-containing products. (5.1)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir is a multi-organ clinical syndrome. (5.1)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Patients who carry the HLA-B*5701 allele are at high risk for experiencing a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir. (5.1)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Discontinue TRIZIVIR as soon as a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected. Regardless of HLA-B*5701 status, permanently discontinue TRIZIVIR if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out. (5.1)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, NEVER restart TRIZIVIR or any other abacavir-containing product. (5.1)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Hematologic toxicity, including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, has been associated with the use of zidovudine, a component of TRIZIVIR. (5.2)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with prolonged use of zidovudine. (5.3)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. (5.4)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) and have discontinued lamivudine, a component of TRIZIVIR. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B treatment. (5.5)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">TRIZIVIR, a combination of abacavir, lamivudine, and zidovudine, each nucleoside analogue HIV-1 reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (1)  (<a href="#section-1">1</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>A medication guide and warning card should be dispensed with each new prescription and refill. (2)</dd>
<dt>â€¢</dt>
<dd>Adults and Adolescents: 1 tablet twice daily. (2.1)</dd>
<dt>â€¢</dt>
<dd>Not recommended in adolescents who weigh less than 40Â kg. (2.1)</dd>
<dt>â€¢</dt>
<dd>Do not prescribe for patients requiring dosage adjustment or patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (2.2)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets contain 300Â mg abacavir, 150Â mg of lamivudine, and 300Â mg of zidovudine. (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir or any other component of the product. (4, 5.1, 6)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>. (4)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>See boxed warning for information about the following: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, hematologic toxicity, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, and severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B. (5.1, 5.2, 5.3, 5.4, 5.5) </dd>
<dt>â€¢</dt>
<dd>Hepatic decompensation, some fatal, has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy and interferon alfa with or without ribavirin. Discontinue TRIZIVIR as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both. (5.6)</dd>
<dt>â€¢</dt>
<dd>Exacerbation of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> has been reported in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine. Coadministration of ribavirin and zidovudine is not advised. (5.6)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> (5.7) and redistribution/accumulation of body fat (5.8) have been reported in patients treated with combination antiretroviral therapy.</dd>
<dt>â€¢</dt>
<dd>TRIZIVIR should not be administered with other products containing abacavir, lamivudine, or zidovudine; or with emtricitabine. (5.11)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most commonly reported adverse reactions (incidence â‰¥10%) in clinical trials were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (6.1)Â  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-FDA-1088 or <a href="#_Ref">www.fda.gov/medwatch</a>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Concomitant use with the following drugs should be avoided: stavudine (7.1), doxorubicin (7.2).</dd>
<dt>â€¢</dt>
<dd>Ethanol: Decreases the elimination of abacavir. (7.3)</dd>
<dt>â€¢</dt>
<dd>Bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine. (7.4)</dd>
<dt>â€¢</dt>
<dd>Methadone: An increased methadone dose may be required in a small number of patients. (7.6)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 4/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, HEMATOLOGIC TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span>, EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adults and Adolescent Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage Adjustment</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc"></a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Hematologic Toxicity/Bone Marrow Suppression</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> With Steatosis</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Patients With HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Use With Interferon- and Ribavirin-Based Regimens</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Fat Redistribution</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Therapy Experienced Patients</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Use With Other Abacavir-, Lamivudine-, Zidovudine-, and/or Emtricitabine-Containing Products</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Antiretroviral Agents</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Doxorubicin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Ethanol</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Hematologic/Bone Marrow Suppressive/Cytotoxic Agents</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Interferon- and Ribavirin-Based Regimens</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Methadone</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Trimethoprim/Sulfamethoxazole (TMP/SMX)</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Patients With Impaired Hepatic Function</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_5647ee07-1228-4d00-ab2a-b45195705999"></a><a name="section-1"></a><p></p>
<h1>WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, HEMATOLOGIC TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span>, EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>: Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been associated with abacavir sulfate, a component of TRIZIVIR. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir is a multi-organ clinical syndrome usually characterized by a sign or symptom in 2 or more of the following groups: (1) <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, (2) <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, (3) gastrointestinal (including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>), (4) constitutional (including generalized <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or achiness), and (5) respiratory (including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>). Discontinue TRIZIVIR as soon as a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected.</span></p>
<p><span class="Bold">Patients who carry the HLA-B*5701 allele are at high risk for experiencing a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir. Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. HLA-B*5701-negative patients may develop a suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</span></p>
<p><span class="Bold">Regardless of HLA-B*5701 status, permanently discontinue TRIZIVIR if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, even when other diagnoses are possible.</span></p>
<p><span class="Bold">Following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, NEVER restart TRIZIVIR or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
<p><span class="Bold">Reintroduction of TRIZIVIR or any other abacavir-containing product, even in patients who have no identified history or unrecognized symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir therapy, can result in serious or fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. Such reactions can occur within hours<span class="Italics"> [see Warnings and Precautions (5.1)]</span>.</span></p>
<p><span class="Bold">Hematologic Toxicity: Zidovudine, a component of TRIZIVIR, has been associated with hematologic toxicity, including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, particularly in patients with advanced Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus (HIV-1) disease <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>: Prolonged use of zidovudine has been associated with symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span>: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including abacavir, lamivudine, zidovudine, and other antiretrovirals <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</span></p>
<p><span class="Bold">Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B: Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and HIV-1 and have discontinued lamivudine, which is one component of TRIZIVIR. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue TRIZIVIR and are co-infected with HIV-1 and HBV. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted <span class="Italics">[see Warnings and Precautions (5.5)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_e410fc6f-40ab-4384-a947-a4e2a648cf13"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"> TRIZIVIR is indicated in combination with other antiretrovirals or alone for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p> Additional important information on the use of TRIZIVIR for treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:</p>
<dl>
<dt>â€¢</dt>
<dd>TRIZIVIR is one of multiple products containing abacavir. Before starting TRIZIVIR, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir <span class="Italics">[see Warnings and Precautions (5.1), Adverse Reactions (6)]</span>.</dd>
<dt>â€¢</dt>
<dd>TRIZIVIR is a fixed-dose combination of 3Â nucleoside analogues: abacavir, lamivudine, and zidovudine and is intended only for patients whose regimen would otherwise include these 3Â components.</dd>
<dt>â€¢</dt>
<dd>Limited data exist on the use of TRIZIVIR alone in patients with higher baseline viral load levels (&gt;100,000Â copies/mL) <span class="Italics">[see Clinical Studies (14)]</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_21747141-55fd-44fc-9633-d52b90a038cc"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<dl>
<dt>â€¢</dt>
<dd>A Medication Guide and Warning Card that provide information about recognition of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> should be dispensed with each new prescription and refill. </dd>
<dt>â€¢</dt>
<dd>TRIZIVIR can be taken with or without food.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_82a64677-1351-4d74-b972-c99f2ff72a3f"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adults and Adolescent Patients</h2>
<p class="First">The recommended oral dose of TRIZIVIR is one tablet twice daily.</p>
<p> TRIZIVIR is not recommended in adolescents who weigh less than 40Â kg because it is a fixed-dose tablet and cannot be dose adjusted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b994d4bc-bb4a-4770-98cb-a66da9e913b4"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage Adjustment</h2>
<p class="First">Because it is a fixed-dose combination, TRIZIVIR should not be prescribed for:</p>
<dl>
<dt>â€¢</dt>
<dd>patients requiring dosage adjustment such as those with creatinine clearance &lt;50Â mL/min.</dd>
<dt>â€¢</dt>
<dd>patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_d086388c-4584-4c6b-9462-847da1101355"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"> TRIZIVIR Tablets contain 300Â mg of abacavir as abacavir sulfate, 150Â mg of lamivudine, and 300Â mg of zidovudine. The tablets are blue-green, capsule-shaped, film-coated, and imprinted with â€œGX LL1â€? on one side with no markings on the reverse side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_e531fa42-5ef1-4188-8a44-1f5514af87ba"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First"> TRIZIVIR Tablets are contraindicated in patients with:</p>
<dl>
<dt>â€¢</dt>
<dd>previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir or any other component of the product. NEVER restart TRIZIVIR or any other abacavir-containing product following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, regardless of HLA-B*5701 status <span class="Italics">[see Warnings and Precautions (5.1), Adverse Reactions (6)]</span>.</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Use in Specific Populations (8.7)]</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8fa31d5c-0862-40d8-babd-19adeb395ba2"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></h2>
<p class="First"> Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been associated with TRIZIVIR and other abacavir-containing products. Patients who carry the HLA-B*5701 allele are at high risk for experiencing a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir. Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.</p>
<p> HLA-B*5701-negative patients may develop a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. Regardless of HLA-B*5701 status, permanently discontinue TRIZIVIR if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, even when other diagnoses are possible.</p>
<p> Important information on signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, as well as clinical management, is presented below.</p>
<p><span class="Underline">Signs and Symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir is a multi-organ clinical syndrome usually characterized by a sign or symptom in 2 or more of the following groups.</p>
<p> Group 1: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p>
<p> Group 2: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p>
<p> Group 3: Gastrointestinal (including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>)</p>
<p> Group 4: Constitutional (including generalized <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or achiness)</p>
<p> Group 5: Respiratory (including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>)</p>
<p> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir following the presentation of a single sign or symptom has been reported infrequently.</p>
<p> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir was reported in approximately 8% of 2,670Â subjects (nÂ =Â 206) in 9Â clinical trials (range: 2% to 9%) with enrollment from November 1999 to February 2002. Data on time to onset and symptoms of suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> were collected on a detailed data collection module. The frequencies of symptoms are shown in Figure 1. Symptoms usually appeared within the first 6Â weeks of treatment with abacavir, although the reaction may occur at any time during therapy. Median time to onset was 9Â days; 89% appeared within the first 6Â weeks; 95% of subjects reported symptoms from 2 or more of theÂ 5 groups listed above.</p>
<p> A trial with ZIAGEN<span class="Sup">Â®</span> (abacavir sulfate) used double-blind ascertainment of suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. During the blinded portion of the trial, suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir was reported by investigators in 9% of 324Â subjects in the abacavir group and 3% of 325Â subjects in the zidovudine group.</p>
<p><span class="Bold">Figure 1. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>-Related Symptoms Reported With â‰¥10% Frequency in Clinical Trials (nÂ =Â 206 Subjects)</span></p>
<p><a name="id412"></a><img alt="Figure 1." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3354e50f-4dc5-413f-b5ae-87353ab8913d&amp;name=087d00b2-8d76-49ca-a78a-a05ecfba0835-01.jpg"></p>
<p> Other less common signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> include <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, myolysis, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, abnormal chest x-ray findings (predominantly infiltrates, which can be localized), and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">adult respiratory distress syndrome</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have occurred in association with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>.</p>
<p> Physical findings associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir in some subjects include <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, mucous membrane lesions (<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulcerations</span>), and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. The <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> usually appears maculopapular or urticarial, but may be variable in appearance. There have been reports of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have occurred without <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p> Laboratory abnormalities associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir in some subjects include elevated liver function tests, elevated creatinine phosphokinase, elevated creatinine, and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>.</p>
<p><span class="Underline">Clinical Management of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> Discontinue TRIZIVIR as soon as a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected. To minimize the risk of a life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, permanently discontinue TRIZIVIR if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, even when other diagnoses are possible (e.g., acute onset respiratory diseases such as <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, or <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>; <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>; or reactions to other medications).</p>
<p> Following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, NEVER restart TRIZIVIR or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p> When therapy with TRIZIVIR has been discontinued for reasons other than symptoms of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, and if reinitiation of abacavir is under consideration, carefully evaluate the reason for discontinuation to ensure that the patient did not have symptoms of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of TRIZIVIR.</p>
<p> If <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, DO NOT reintroduce TRIZIVIR or any other abacavir-containing product. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</p>
<p> If symptoms consistent with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> are not identified, reintroduction can be undertaken with continued monitoring for symptoms of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. Make patients aware that a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> can occur with reintroduction of abacavir and that abacavir reintroduction needs to be undertaken only if medical care can be readily accessed by the patient or others.</p>
<p><span class="Underline">Risk Factor:</span><span class="Italics">HLA-B*5701 Allele:</span> Trials have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir.</p>
<p> CNA106030 (PREDICT-1), a randomized, double-blind trial, evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> in abacavir-naive HIV-1-infected adults (nÂ =Â 1,650). In this trial, use of pre-therapy screening for the HLA-B*5701 allele and exclusion of subjects with this allele reduced the incidence of clinically suspected abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> from 7.8% (66/847) to 3.4% (27/803). Based on this trial, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele.</p>
<p> Screening for carriage of the HLA-B*5701 allele is recommended prior to initiating treatment with abacavir. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk.</p>
<p> Skin patch testing is used as a research tool and should not be used to aid in the clinical diagnosis of abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p> In any patient treated with abacavir, the clinical diagnosis of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> must remain the basis of clinical decision-making. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_31f187f0-0698-4dcf-b5c7-1c4f9d990cd2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Hematologic Toxicity/Bone Marrow Suppression</h2>
<p class="First"> Zidovudine, a component of TRIZIVIR, has been associated with hematologic toxicity including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, particularly in patients with advanced HIV-1 disease. TRIZIVIR should be used with caution in patients who have bone marrow compromise evidenced by granulocyte count less than 1,000Â cells/mm<span class="Sup">3</span> or hemoglobin less than 9.5Â g/dL.</p>
<p> Frequent blood counts are strongly recommended in patients with advanced HIV-1 disease who are treated with TRIZIVIR. Periodic blood counts are recommended for other HIV-1-infected patients. If <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> develops, dosage interruption may be needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb7cd318-5278-4d32-9665-862c8589f3fa"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, with pathological changes similar to that produced by HIV-1 disease, have been associated with prolonged use of zidovudine, and therefore may occur with therapy with TRIZIVIR.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_149cc858-711e-4277-bf31-d3ab7af82631"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> With Steatosis</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including abacavir, lamivudine, zidovudine, and other antiretrovirals. A majority of these cases have been in women. <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span> and prolonged nucleoside exposure may be risk factors. Particular caution should be exercised when administering TRIZIVIR to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with TRIZIVIR should be suspended in any patient who develops clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_482a9805-1197-4900-a177-ef405ebc959b"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Patients With HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></h2>
<p class="First"><span class="Underline">Posttreatment Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>:</span> In clinical trials in non-HIV-1-infected subjects treated with lamivudine for chronic HBV, clinical and laboratory evidence of exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have occurred after discontinuation of lamivudine. These exacerbations have been detected primarily by serum ALT elevations in addition to re-emergence of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B viral DNA (HBV DNA). Although most events appear to have been self-limited, fatalities have been reported in some cases. Similar events have been reported from post-marketing experience after changes from lamivudine-containing HIV-1 treatment regimens to non-lamivudine-containing regimens in patients infected with both HIV-1 and HBV. The causal relationship to discontinuation of lamivudine treatment is unknown. Patients should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. There is insufficient evidence to determine whether reinitiation of lamivudine alters the course of posttreatment exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
<p><span class="Underline">Emergence of Lamivudine-Resistant HBV:</span> Safety and efficacy of lamivudine have not been established for treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B in subjects dually infected with HIV-1 and HBV. In non-HIV-infected subjects treated with lamivudine for chronic hepatitisÂ B, emergence of lamivudine-resistant HBV has been detected and has been associated with diminished treatment response (see full prescribing information for EPIVIR-HBV<span class="Sup">Â®</span> [lamivudine] for additional information). Emergence of hepatitisÂ B virus variants associated with resistance to lamivudine has also been reported in HIV-1-infected subjects who have received lamivudine-containing antiretroviral regimens in the presence of concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with hepatitisÂ B virus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2edac4a-3fdc-4063-b393-e7d2bb2876c9"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Use With Interferon- and Ribavirin-Based Regimens</h2>
<p class="First">InÂ vitro studies have shown ribavirin can reduce the phosphorylation of pyrimidine nucleoside analogues such as lamivudine and zidovudine. Although no evidence of a pharmacokinetic or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> (e.g., loss of HIV-1/HCV virologic suppression) was seen when ribavirin was coadministered with lamivudine or zidovudine in HIV-1/HCV co-infected subjects <span class="Italics">[see Clinical Pharmacology (12.3)]</span>, hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected subjects receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin. Patients receiving interferon alfa with or without ribavirin and TRIZIVIR should be closely monitored for treatment-associated toxicities, especially hepatic decompensation, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Discontinuation of TRIZIVIR should be considered as medically appropriate. Dose reduction or discontinuation of interferon alfa, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Child-Pugh greater than 6) (see the complete prescribing information for interferon and ribavirin).</p>
<p> Exacerbation of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> has been reported in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine. Coadministration of ribavirin and TRIZIVIR is not advised.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d1592c75-9848-4410-9fb3-9da1497efff3"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including TRIZIVIR. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jirovecii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> [PCP], or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment.</p>
<p><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Gravesâ€™ disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-BarrÃ© syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d49151f7-fcc4-47b1-b535-66c4bc9f681a"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Fat Redistribution</h2>
<p class="First"> Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and â€œcushingoid appearanceâ€? have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4df4756a-7461-466f-9c5f-e2842edccf08"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">In a published prospective, observational, epidemiological trial designed to investigate the rate of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in patients on combination antiretroviral therapy, the use of abacavir within the previous 6Â months was correlated with an increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI).<span class="Sup">1</span> In a sponsor-conducted pooled analysis of clinical trials, no excess risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> was observed in abacavir-treated subjects as compared with control subjects. In totality, the available data from the observational cohort and from clinical trials are inconclusive.</p>
<p> As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, smoking).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f09e4c46-aae1-41e6-9b74-e4b3dc626059"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Therapy Experienced Patients</h2>
<p class="First">In clinical trials, subjects with prolonged prior nucleoside reverse transcriptase inhibitor (NRTI) exposure or who had HIV-1 isolates that contained multiple mutations conferring resistance to NRTIs had limited response to abacavir. The potential for cross-resistance between abacavir and other NRTIs should be considered when choosing new therapeutic regimens in therapy-experienced patients <span class="Italics">[see Clinical Pharmacology (12.4)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_46475cfd-f53a-4bc1-820e-59841fcffebb"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Use With Other Abacavir-, Lamivudine-, Zidovudine-, and/or Emtricitabine-Containing Products</h2>
<p class="First">TRIZIVIR is a fixed-dose combination of abacavir, lamivudine, and zidovudine and is intended only for patients whose regimen would otherwise include these 3Â components. TRIZIVIR should not be administered concomitantly with other abacavir-, lamivudine-, or zidovudine-containing products including ZIAGEN (abacavir sulfate) Tablets and Oral Solution, EPIVIR<span class="Sup">Â®</span> (lamivudine) Tablets and Oral Solution, EPIVIR-HBV (lamivudine) Tablets and Oral Solution, RETROVIR<span class="Sup">Â®</span> (zidovudine) Tablets, Capsules, Syrup, and IV Infusion, COMBIVIR<span class="Sup">Â®</span> (lamivudine and zidovudine) Tablets, EPZICOM<span class="Sup">Â®</span> (abacavir sulfate and lamivudine) Tablets; or emtricitabineâ€‘containing products, including ATRIPLA<span class="Sup">Â®</span> (efavirenz/emtricitabine/tenofovir disoproxil fumarate) Tablets, EMTRIVA<span class="Sup">Â®</span> (emtricitabine) Capsules and Oral Solution, TRUVADA<span class="Sup">Â®</span> (emtricitabine/tenofovir disoproxil fumarate) Tablets, or COMPLERA<span class="Sup">Â®</span> (emtricitabine/rilpirivine/tenofovir disoproxil fumarate) Tablets.</p>
<p>The complete prescribing information for all agents being considered for use with TRIZIVIR should be consulted before combination therapy with TRIZIVIR is initiated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_4eba6b85-172c-4e80-a304-f18352713cf3"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First"> The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<dl>
<dt>â€¢</dt>
<dd>Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1)]</span>.</dd>
<dt>â€¢</dt>
<dd>Hematologic toxicity, including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span><span class="Italics"> [see Boxed Warning, Warnings and Precautions (5.2)]</span>.</dd>
<dt>â€¢</dt>
<dd>Symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.3)]</span>.</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.4)]</span>.</dd>
<dt>â€¢</dt>
<dd>Acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.5)]</span>.</dd>
<dt>â€¢</dt>
<dd>Hepatic decompensation in patients co-infected with HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="Italics">[see Warnings and Precautions (5.6)]</span>.</dd>
<dt>â€¢</dt>
<dd>Exacerbation of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine <span class="Italics">[see Warnings and Precautions (5.6)]</span>.</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> <span class="Italics">[see Warnings and Precautions (5.7)]</span>.</dd>
<dt>â€¢</dt>
<dd>Fat redistribution <span class="Italics">[see Warnings and Precautions (5.8)]</span>.</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> <span class="Italics">[see Warnings and Precautions (5.9)]</span>.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49196300-a3ca-4b1d-af1d-4eec9e9e3091"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p> Treatment-emergent clinical adverse reactions (rated by the investigator as moderate or severe) with a frequency greater than or equal to 5% during therapy with abacavir 300Â mg twice daily, lamivudine 150Â mg twice daily, and zidovudine 300Â mg twice daily compared with indinavir 800Â mg 3Â times daily, lamivudine 150Â mg twice daily, and zidovudine 300Â mg twice daily from CNA3005 are listed in TableÂ 1.</p>
<a name="_Refid_672d9f61-2094-44d5-99e8-1bb3126f0"></a><table>
<caption><span>Table 1. Treatment-Emergent (All Causality) Adverse Reactions of at Least Moderate Intensity (Grades 2-4, â‰¥5% Frequency) in Therapy-Naive Adults (CNA3005) Through 48Â Weeks of Treatment</span></caption>
<col width="27%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Adverse Reaction</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First">ZIAGEN plus</p>
<p>Lamivudine/Zidovudine</p>
<p>(nÂ =Â 262)</p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First">Indinavir plus</p>
<p>Lamivudine/Zidovudine</p>
<p>(nÂ =Â 264)</p>
</td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">19%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">17%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">13%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">9%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">12%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">12%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">10%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reaction</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">8%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">7%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and/or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">6%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive disorders</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">6%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Ear/nose/<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Viral <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infections</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Renal signs/symptoms</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">&lt;1%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> (non-site-specific)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">&lt;1%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5%</p></td>
</tr>
</tbody>
</table>
<p>Five subjects receiving abacavir in CNA3005 experienced worsening of pre-existing <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> compared to none in the indinavir arm. The background rates of pre-existing <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> were similar in the 2Â treatment arms.</p>
<p><span class="Underline">Laboratory Abnormalities:</span> Laboratory abnormalities in CNA3005 are listed in Table 2.</p>
<a name="_Refid_183f38f3-4f13-4fd7-a5f7-45a3b815e"></a><table>
<caption><span>Table 2. Treatment-Emergent Laboratory Abnormalities (Grades 3/4) in CNA3005</span></caption>
<col width="36%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First">Grade 3/4 Laboratory Abnormalities</p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">Number of Subjects by Treatment Group</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">ZIAGEN plus</p>
<p>Lamivudine/Zidovudine</p>
<p>(nÂ =Â 262)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Indinavir plus</p>
<p>Lamivudine/Zidovudine</p>
<p>(nÂ =Â 264)</p>
</td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Elevated CPK (&gt;4 x ULN)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">18 (7%)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">18 (7%)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">ALT (&gt;5.0 x ULN)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">16 (6%)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">16 (6%)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (&lt;750/mm<span class="Sup">3</span>)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">13 (5%)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">13 (5%)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> (&gt;750Â mg/dL)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5 (2%)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">3 (1%)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Hyperamylasemia (&gt;2.0 x ULN)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5 (2%)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> (&gt;13.9Â mmol/L)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">2 (&lt;1%)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">2 (&lt;1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (Hgb â‰¤6.9Â g/dL)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0 (0%)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (1%)</p></td>
</tr>
<tr><td class="Lrule Rrule" colspan="3" valign="top"><p class="First">ULNÂ =Â Upper limit of normal.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="3" valign="top"><p class="First">nÂ =Â Number of patients assessed.</p></td></tr>
</tbody>
</table>
<p><span class="Underline">Other Adverse Events:</span> In addition to adverse reactions in Tables 1 and 2, other adverse events observed in the expanded access program for abacavir were <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and increased GGT.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ee23db6-0beb-4053-bef8-506c8db53d4a"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">In addition to adverse reactions reported from clinical trials, the following reactions have been identified during postmarketing use of abacavir, lamivudine, and/or zidovudine. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to abacavir, lamivudine and/or zidovudine.</p>
<p><span class="Underline">Abacavir:</span></p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>.</p>
<p><span class="Italics">Skin:</span> Suspected <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS) and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN) have been reported in patients receiving abacavir primarily in combination with medications known to be associated with SJS and TEN, respectively. Because of the overlap of clinical signs and symptoms between <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir and SJS and TEN, and the possibility of multiple drug sensitivities in some patients, abacavir should be discontinued and not restarted in such cases.</p>
<p> There have also been reports of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> with abacavir use.</p>
<p><span class="Underline">Abacavir, Lamivudine, and/or Zidovudine:</span></p>
<p><span class="Italics">Body as a Whole:</span> Redistribution/accumulation of body fat <span class="Italics">[see Warnings and Precautions (5.8)]</span>.</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>.</p>
<p><span class="Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>.</p>
<p><span class="Italics">Endocrine and Metabolic:</span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> and/or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, oral mucosal <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>.</p>
<p><span class="Italics">General:</span> <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</p>
<p><span class="Italics">Hemic and Lymphatic:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (including pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span> and severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span> progressing on therapy), <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Italics">Hepatic:</span> <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span> <span class="Italics">[see Warnings and Precautions (5.4)]</span>, elevated bilirubin, elevated transaminases, posttreatment exacerbation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="Italics">[see Warnings and Precautions (5.5)]</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> Sensitization reactions (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, CPK elevation, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p><span class="Italics">Nervous:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p><span class="Italics">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> and other <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span>.</p>
<p><span class="Italics">Respiratory:</span> Abnormal breath sounds/<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>.</p>
<p><span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_6dd7ebeb-8204-49c4-b560-69edc59e4a19"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<dl>
<dt>â€¢</dt>
<dd>No drug interaction trials have been conducted using TRIZIVIR Tablets <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_665602f5-b69a-4b5c-bb29-3c1fdfcd2f09"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Antiretroviral Agents</h2>
<p class="First"><span class="Underline">Zidovudine:</span><span class="Italics">Stavudine:</span> Concomitant use of zidovudine with stavudine should be avoided since an antagonistic relationship has been demonstrated inÂ vitro.</p>
<p><span class="Italics">Nucleoside Analogues Affecting DNA Replication:</span> Some nucleoside analogues affecting DNA replication, such as ribavirin, antagonize the inÂ vitro antiviral activity of zidovudine against HIV-1; concomitant use of such drugs should be avoided.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d77a4811-edea-4185-88d2-66bffbf3eaee"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Doxorubicin</h2>
<p class="First"><span class="Underline">Zidovudine:</span> Concomitant use of zidovudine with doxorubicin should be avoided since an antagonistic relationship has been demonstrated inÂ vitro.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c82e9e23-dbf9-46c4-b58a-3aa3d32aac00"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Ethanol</h2>
<p class="First"><span class="Underline">Abacavir:</span> Abacavir has no effect on the pharmacokinetic properties of ethanol. Ethanol decreases the elimination of abacavir causing an increase in overall exposure <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d7b47f31-3d15-4c11-ae1e-ca2d3bbf6616"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Hematologic/Bone Marrow Suppressive/Cytotoxic Agents</h2>
<p class="First"><span class="Underline">Zidovudine:</span> Coadministration of ganciclovir, interferon alfa, ribavirin, and other bone marrow suppressive or cytotoxic agents may increase the hematologic toxicity of zidovudine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_458824ed-6e43-4703-b749-b7d8df44a4f9"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Interferon- and Ribavirin-Based Regimens</h2>
<p class="First"><span class="Underline">Lamivudine:</span> Although no evidence of a pharmacokinetic or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> (e.g., loss of HIV-1/HCV virologic suppression) was seen when ribavirin was coadministered with lamivudine in HIV-1/HCV co-infected subjects, hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected subjects receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin <span class="Italics">[see Warnings and Precautions (5.6), Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_33febdf2-956f-4cd0-831f-c5e7f367a249"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Methadone</h2>
<p class="First"><span class="Underline">Abacavir:</span> The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. In a trial of 11Â HIV-1-infected subjects receiving methadone-maintenance therapy with 600Â mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased <span class="Italics">[see Clinical Pharmacology (12.3)]</span>. This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f9aaedb8-32e3-4669-b4cc-9f1afecc08af"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Trimethoprim/Sulfamethoxazole (TMP/SMX)</h2>
<p class="First"><span class="Underline">Lamivudine:</span> No change in dose of either drug is recommended <span class="Italics">[see Clinical Pharmacology (12.3)]</span>. There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat PCP.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_db3d1e1c-60c1-49ee-8f04-bd58c74a65f3"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_bfc864ca-6305-40d3-a5b0-076e3c31490a"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Underline">TRIZIVIR:</span> Pregnancy Category C. There are no adequate and well-controlled studies of TRIZIVIR in pregnant women. Reproduction studies with abacavir, lamivudine, and zidovudine have been performed in animals (see Abacavir, Lamivudine, and Zidovudine sections below). TRIZIVIR should be used during pregnancy only if the potential benefits outweigh the risks.</p>
<p><span class="Underline">Abacavir:</span> Studies in pregnant rats showed that abacavir is transferred to the fetus through the placenta. <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">Fetal malformations</span> (increased incidences of fetal <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">anasarca</span> and skeletal malformations) and developmental toxicity (depressed fetal body weight and reduced crown-rump length) were observed in rats at a dose which produced 35Â times the human exposure, based on AUC. Embryonic and fetal toxicities (increased resorptions, decreased fetal body weights) and toxicities to the offspring (increased incidence of <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span> and lower body weights) occurred at half of the above-mentioned dose in separate fertility studies conducted in rats. In the rabbit, no developmental toxicity and no increases in <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> occurred at doses that produced 8.5Â times the human exposure at the recommended dose based on AUC.</p>
<p><span class="Underline">Lamivudine:</span> Studies in pregnant rats showed that lamivudine is transferred to the fetus through the placenta. Reproduction studies with orally administered lamivudine have been performed in rats and rabbits at doses producing plasma levels up to approximately 35Â times that for the recommended adult HIV dose. No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> due to lamivudine was observed. Evidence of early embryolethality was seen in the rabbit at exposure levels similar to those observed in humans, but there was no indication of this effect in the rat at exposure levels up to 35Â times those in humans.</p>
<p><span class="Underline">Zidovudine:</span> Reproduction studies with orally administered zidovudine in the rat and in the rabbit at doses up to 500Â mg/kg/day revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> with zidovudine. Zidovudine treatment resulted in embryo/fetal toxicity as evidenced by an increase in the incidence of fetal resorptions in rats given 150 or 450Â mg/kg/day and rabbits given 500Â mg/kg/day. The doses used in the teratology studies resulted in peak zidovudine plasma concentrations (after one half of the daily dose) in rats 66 to 226Â times, and in rabbits 12 to 87Â times, mean steady-state peak human plasma concentrations (after one sixth of the daily dose) achieved with the recommended daily dose (100Â mg every 4Â hours). In an additional teratology study in rats, a dose of 3,000Â mg/kg/day (very near the oral median lethal dose in rats of approximately 3,700Â mg/kg) caused marked maternal toxicity and an increase in the incidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. This dose resulted in peak zidovudine plasma concentrations 350Â times peak human plasma concentrations. No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was seen in this experiment at doses of 600Â mg/kg/day or less. Two rodent carcinogenicity studies were conducted<span class="Italics"> [see Nonclinical Toxicology (13.1)]</span>.</p>
<p><span class="Underline">Antiretroviral Pregnancy Registry:</span> To monitor maternal-fetal outcomes of pregnant women exposed to TRIZIVIR or other antiretroviral agents, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_6eb27afc-582a-45dd-85ce-467b464e8863"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First"> The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>.</p>
<p><span class="Underline">Abacavir, Lamivudine, and Zidovudine:</span> Lamivudine and zidovudine are excreted in human breast milk; abacavir and lamivudine are secreted into the milk of lactating rats.</p>
<p> Because of both the potential for HIV-1 transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed if they are receiving TRIZIVIR.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_9b4e2767-efc8-4403-80a4-ad3a333787f9"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">TRIZIVIR is not intended for use in pediatric patients and is not recommended in adolescents who weigh less than 40Â kg because it is a fixed-dose tablet that cannot be adjusted for these patient populations.</p>
<p><span class="Underline">Therapy-Experienced Pediatric Trial:</span> A randomized, double-blind trial, CNA3006, compared ZIAGEN plus lamivudine and zidovudine versus lamivudine and zidovudine in pediatric subjects, most of whom were extensively pretreated with nucleoside analogue antiretroviral agents. Subjects in this trial had a limited response to abacavir.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_44f0040f-3bad-4ac0-b976-7c08800b11fd"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of abacavir, lamivudine, and zidovudine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy <span class="Italics">[see Dosage and Administration (2.3), Use in Specific Populations (8.6)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a9f20981-9159-4c9e-b97b-05f6693505f0"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">TRIZIVIR is not recommended for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (i.e., creatinine clearance &lt;50Â mL/min) because TRIZIVIR is a fixed-dose combination and the dosage of the individual components cannot be adjusted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_346b59ad-19dd-4701-8f90-9e6ca229444d"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Patients With Impaired Hepatic Function</h2>
<p class="First">TRIZIVIR is contraindicated for patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> because TRIZIVIR is a fixed-dose combination and the dosage of the individual components cannot be adjusted.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_e0883345-1b18-4e28-bbfc-38fa71ea36ec"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="Bold">Abacavir:</span> There is no known antidote for abacavir. It is not known whether abacavir can be removed by peritoneal dialysis or hemodialysis.</p>
<p><span class="Bold">Lamivudine:</span> One case of an adult ingesting 6Â grams of lamivudine was reported; there were no clinical signs or symptoms noted and hematologic tests remained normal. It is not known whether lamivudine can be removed by peritoneal dialysis or hemodialysis.</p>
<p><span class="Bold">Zidovudine:</span> <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Acute overdoses</span> of zidovudine have been reported in pediatric patients and adults. These involved exposures up to 50Â grams. The only consistent findings were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Other reported occurrences included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. Hematologic changes were transient. All patients recovered. Hemodialysis and peritoneal dialysis appear to have a negligible effect on the removal of zidovudine, while elimination of its primary metabolite, 3â€²-azido-3â€²-deoxy-5â€²-<span class="Italics">O</span>-Î²-<span class="Italics">D</span>-glucopyranuronosylthymidine (GZDV), is enhanced.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_335fc867-4a81-4aa3-a44d-bf270c7d020b"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First"><span class="Bold">TRIZIVIR:</span> TRIZIVIR Tablets contain the following 3 synthetic nucleoside analogues: abacavir sulfate (ZIAGEN), lamivudine (also known as EPIVIR or 3TC), and zidovudine (also known as RETROVIR, azidothymidine, or ZDV) with inhibitory activity against HIV-1.</p>
<p> TRIZIVIR Tablets are for oral administration. Each film-coated tablet contains the active ingredients 300Â mg of abacavir as abacavir sulfate, 150Â mg of lamivudine, and 300Â mg of zidovudine, and the inactive ingredients magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The tablets are coated with a film (OPADRY<span class="Sup">Â®</span> green 03B11434) that is made of FD&amp;C Blue No. 2, hypromellose, polyethylene glycol, titanium dioxide, and yellow iron oxide.</p>
<p><span class="Bold">Abacavir Sulfate:</span> The chemical name of abacavir sulfate is <span class="Italics">(</span>1<span class="Italics">S,cis)-</span>4-[2-amino-6-(cyclopropylamino)-9<span class="Italics">H</span>-purin-9-yl]-2-cyclopentene-1-methanol sulfate (salt) (2:1). Abacavir sulfate is the enantiomer with <span class="Italics">1S</span>, <span class="Italics">4R</span> absolute configuration on the cyclopentene ring. It has a molecular formula of (C<span class="Sub">14</span>H<span class="Sub">18</span>N<span class="Sub">6</span>O)<span class="Sub">2â€¢</span>H<span class="Sub">2</span>SO<span class="Sub">4</span> and a molecular weight of 670.76 daltons. It has the following structural formula:</p>
<p><a name="id965"></a><img alt="abacavir sulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3354e50f-4dc5-413f-b5ae-87353ab8913d&amp;name=087d00b2-8d76-49ca-a78a-a05ecfba0835-02.jpg"></p>
<p>Abacavir sulfate is a white to off-white solid with a solubility of approximately 77Â mg/mL in distilled water at 25Â°C.</p>
<p> In vivo, abacavir sulfate dissociates to its free base, abacavir. In this insert, all dosages for ZIAGEN (abacavir sulfate) are expressed in terms of abacavir.</p>
<p><span class="Bold">Lamivudine:</span> The chemical name of lamivudine is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one. Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (-)2â€²,3â€²-dideoxy, 3â€²-thiacytidine. It has a molecular formula of C<span class="Sub">8</span>H<span class="Sub">11</span>N<span class="Sub">3</span>O<span class="Sub">3</span>S and a molecular weight of 229.3 daltons. It has the following structural formula:</p>
<p><a name="id974"></a><img alt="lamivudine" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3354e50f-4dc5-413f-b5ae-87353ab8913d&amp;name=087d00b2-8d76-49ca-a78a-a05ecfba0835-03.jpg"></p>
<p>Lamivudine is a white to off-white crystalline solid with a solubility of approximately 70Â mg/mL in water at 20Â°C.</p>
<p><span class="Bold">Zidovudine: </span>The chemical name of zidovudine is 3â€²-azido-3â€²-deoxythymidine. It has a molecular formula of C<span class="Sub">10</span>H<span class="Sub">13</span>N<span class="Sub">5</span>O<span class="Sub">4</span> and a molecular weight of 267.24 daltons. It has the following structural formula:</p>
<p><a name="id982"></a><img alt="zidovudine" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3354e50f-4dc5-413f-b5ae-87353ab8913d&amp;name=087d00b2-8d76-49ca-a78a-a05ecfba0835-04.jpg"></p>
<p>Zidovudine is a white to beige, crystalline solid with a solubility of 20.1Â mg/mL in water at 25Â°C.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_553ce180-f69f-486a-a440-e5e1faf2fb99"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_72c3286a-1ef7-45a3-aee5-1e0f297d311e"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">TRIZIVIR is an antiviral agent <span class="Italics">[see Clinical Pharmacology (12.4)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_7e8ec006-e753-4b50-98ab-ba8acc88343a"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Pharmacokinetics in Adults:</span><span class="Italics">TRIZIVIR:Â  </span>In a single-dose, 3-way crossover bioavailability trial of 1Â TRIZIVIR Tablet versus 1Â ZIAGEN Tablet (300Â mg), 1Â EPIVIR Tablet (150Â mg), plus 1Â RETROVIR Tablet (300Â mg) administered simultaneously in healthy subjects (nÂ =Â 24), there was no difference in the extent of absorption, as measured by the area under the plasma concentration-time curve (AUC) and maximal peak concentration (C<span class="Sub">max</span>), of all 3Â components. One TRIZIVIR Tablet was bioequivalent to 1Â ZIAGEN Tablet (300Â mg), 1Â EPIVIR Tablet (150Â mg), plus 1Â RETROVIR Tablet (300Â mg) following single-dose administration to fasting healthy subjects (nÂ =Â 24).</p>
<p><span class="Italics">Abacavir: </span>Following oral administration, abacavir is rapidly absorbed and extensively distributed. Binding of abacavir to human plasma proteins is approximately 50%. Binding of abacavir to plasma proteins was independent of concentration. Total blood and plasma drug-related radioactivity concentrations are identical, demonstrating that abacavir readily distributes into erythrocytes. The primary routes of elimination of abacavir are metabolism by alcohol dehydrogenase to form the 5â€²-carboxylic acid and glucuronyl transferase to form the 5â€²-glucuronide.</p>
<p><span class="Italics">Lamivudine:</span> Following oral administration, lamivudine is rapidly absorbed and extensively distributed. Binding to plasma protein is low. Approximately 70% of an intravenous dose of lamivudine is recovered as unchanged drug in the urine. Metabolism of lamivudine is a minor route of elimination. In humans, the only known metabolite is the trans-sulfoxide metabolite (approximately 5% of an oral dose after 12Â hours).</p>
<p><span class="Italics">Zidovudine:</span> Following oral administration, zidovudine is rapidly absorbed and extensively distributed. Binding to plasma protein is low. Zidovudine is eliminated primarily by hepatic metabolism. The major metabolite of zidovudine is GZDV. GZDV AUC is about 3-fold greater than the zidovudine AUC. Urinary recovery of zidovudine and GZDV accounts for 14% and 74% of the dose following oral administration, respectively. A second metabolite, 3â€²-amino-3â€²-deoxythymidine (AMT), has been identified in plasma. The AMT AUC was one-fifth of the zidovudine AUC.</p>
<p> In humans, abacavir, lamivudine, and zidovudine are not significantly metabolized by cytochrome P450 enzymes.</p>
<p> The pharmacokinetic properties of abacavir, lamivudine, and zidovudine in fasting subjects are summarized in Table 3.</p>
<a name="_Refid_a8f8d395-6534-469d-8025-80e44e467"></a><table>
<caption><span>Table 3. Pharmacokinetic Parameters<span class="Sup">a</span> for Abacavir, Lamivudine, and Zidovudine in Adults</span></caption>
<col width="39%">
<col width="13%">
<col width="8%">
<col width="13%">
<col width="8%">
<col width="13%">
<col width="7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Parameter</p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">Abacavir</p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">Lamivudine</p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">Zidovudine</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Oral bioavailability (%)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">86Â Â±Â 25</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">nÂ =Â 6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">86 Â± 16</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">nÂ =Â 12</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">64 Â± 10</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">nÂ =Â 5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Apparent volume of distribution (L/kg)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.86 Â± 0.15</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">nÂ =Â 6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.3 Â± 0.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">nÂ =Â 20</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.6 Â± 0.6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">nÂ =Â 8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Systemic clearance (L/h/kg)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.80 Â± 0.24</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">nÂ =Â 6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.33 Â± 0.06</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">nÂ =Â 20</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.6 Â± 0.6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">nÂ =Â 6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Renal clearance (L/h/kg)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">.007 Â± .008</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">nÂ =Â 6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.22Â Â±Â 0.06</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">nÂ =Â 20</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.34 Â± 0.05</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">nÂ =Â 9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Elimination half-life (h)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.45 Â± 0.32</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">nÂ =Â 20</p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First">5 to 7<span class="Sup">b</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First">0.5 to 3<span class="Sup">b</span></p></td>
</tr>
<tr><td class="Lrule Rrule" colspan="7" valign="top"><p class="First"><span class="Sup">a</span> Data presented as mean Â± standard deviation except where noted.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="7" valign="top"><p class="First"><span class="Sup">b</span> Approximate range.</p></td></tr>
</tbody>
</table>
<p><span class="Underline">Effect of Food on Absorption of TRIZIVIR:</span> Administration with food in a single-dose bioavailability trial resulted in lower C<span class="Sub">max</span>, similar to results observed previously for the reference formulations. The average [90% CI] decrease in abacavir, lamivudine, and zidovudine C<span class="Sub">max</span> was 32% [24% to 38%], 18% [10% to 25%], and 28% [13% to 40%], respectively, when administered with a high-fat meal, compared with administration under fasted conditions. Administration of TRIZIVIR with food did not alter the extent of abacavir, lamivudine, and zidovudine absorption (AUC), as compared with administration under fasted conditions (nÂ =Â 24) <span class="Italics">[see Dosage and Administration (2.1)]</span>.</p>
<p><span class="Underline">Special Populations:</span><span class="Italics"> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: TRIZIVIR:</span> Because lamivudine and zidovudine require dose adjustment in the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, TRIZIVIR is not recommended for use in patients with creatinine clearance &lt;50Â mL/min <span class="Italics">[see Use in Specific Populations (8.6)]</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: TRIZIVIR:</span> TRIZIVIR is contraindicated for patients with impaired hepatic function because TRIZIVIR is a fixed-dose combination and the dosage of the individual components cannot be adjusted. Abacavir is contraindicated in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and dose reduction is required in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p><span class="Italics">Pregnancy: See Use in Specific Populations (8.1)</span>.</p>
<p><span class="Italics">Abacavir and Lamivudine:</span> No data are available on the pharmacokinetics of abacavir or lamivudine during pregnancy.</p>
<p><span class="Italics">Zidovudine:</span> Zidovudine pharmacokinetics have been studied in a PhaseÂ 1 trial of 8Â women during the last trimester of pregnancy. As pregnancy progressed, there was no evidence of drug accumulation. The pharmacokinetics of zidovudine were similar to that of nonpregnant adults. Consistent with passive transmission of the drug across the placenta, zidovudine concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery. Although data are limited, methadone maintenance therapy in 5Â pregnant women did not appear to alter zidovudine pharmacokinetics. In a nonpregnant adult population, a potential for interaction has been identified <span class="Italics">[see Use in Specific Populations (8.1)].</span></p>
<p><span class="Italics">Nursing Mothers: See Use in Specific Populations (8.3).</span></p>
<p><span class="Italics">Abacavir:</span> No data are available on the pharmacokinetics of abacavir in nursing mothers.</p>
<p><span class="Italics">Lamivudine:</span> Samples of breast milk obtained from 20Â mothers receiving lamivudine monotherapy (300Â mg twice daily) or combination therapy (150Â mg lamivudine twice daily and 300Â mg zidovudine twice daily) had measurable concentrations of lamivudine.</p>
<p><span class="Italics">Zidovudine:</span> After administration of a single dose of 200Â mg zidovudine to 13Â HIVâ€‘1-infected women, the mean concentration of zidovudine was similar in human milk and serum <span class="Italics">[see Use in Specific Populations (8.3)]</span>.</p>
<p><span class="Italics">Pediatric Patients:</span> TRIZIVIR is not intended for use in pediatric patients. TRIZIVIR is not recommended in adolescents who weigh less than 40Â kg because it is a fixed-dose tablet that cannot be dose adjusted for this patient population.</p>
<p><span class="Italics">Geriatric Patients:</span> The pharmacokinetics of abacavir, lamivudine, and zidovudine have not been studied in subjects over 65Â years of age.</p>
<p><span class="Italics">Gender:</span></p>
<p><span class="Italics">Abacavir: </span>A population pharmacokinetic analysis in HIV-1-infected male (nÂ =Â 304) and female (nÂ =Â 67) subjects showed no gender differences in abacavir AUC normalized for lean body weight.</p>
<p><span class="Italics">Lamivudine and Zidovudine:</span> A pharmacokinetic trial in healthy male (nÂ =Â 12) and female (nÂ =Â 12) subjects showed no gender differences in zidovudine exposure (AUC<span class="Sub">âˆž</span>) or lamivudine (AUC<span class="Sub">âˆž</span>) normalized for body weight.</p>
<p><span class="Italics">Race:</span></p>
<p><span class="Italics">Abacavir:</span> There are no significant differences between blacks and Caucasians in abacavir pharmacokinetics.</p>
<p><span class="Italics">Lamivudine:</span> There are no significant racial differences in lamivudine pharmacokinetics.</p>
<p><span class="Italics">Zidovudine:</span> The pharmacokinetics of zidovudine with respect to race have not been determined.</p>
<p><span class="Underline">Drug Interactions:</span> The drug interactions described below are based on trials conducted with the individual nucleoside analogues.</p>
<p><span class="Italics">Cytochrome P450:</span> In humans, abacavir, lamivudine, and zidovudine are not significantly metabolized by cytochrome P450 enzymes; therefore, it is unlikely that clinically significant drug interactions will occur with drugs metabolized through these pathways.</p>
<p><span class="Italics">Glucuronyl Transferase:</span> Due to the common metabolic pathways of abacavir and zidovudine via glucuronyl transferase, 15Â HIV-1-infected subjects were enrolled in a crossover trial evaluating single doses of abacavir (600Â mg), lamivudine (150Â mg), and zidovudine (300Â mg) alone or in combination. Analysis showed no clinically relevant changes in the pharmacokinetics of abacavir with the addition of lamivudine or zidovudine or the combination of lamivudine and zidovudine. Lamivudine exposure (AUC decreased 15%) and zidovudine exposure (AUC increased 10%) did not show clinically relevant changes with concurrent abacavir.</p>
<p><span class="Italics">Lamivudine and Zidovudine:</span> No clinically significant alterations in lamivudine or zidovudine pharmacokinetics were observed in 12Â asymptomatic HIV-1-infected adult subjects given a single dose of zidovudine (200Â mg) in combination with multiple doses of lamivudine (300Â mg q 12Â h).</p>
<p><span class="Italics">Methadone:</span> In a trial of 11Â HIV-1-infected subjects receiving methadone-maintenance therapy (40Â mg and 90Â mg daily), with 600Â mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI: 6% to 42%) <span class="Italics">[see Drug Interactions (7.6)]</span>.</p>
<p><span class="Italics">Ribavirin:</span> InÂ vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (nÂ =Â 18), stavudine (nÂ =Â 10), or zidovudine (nÂ =Â 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected subjects <span class="Italics">[see Warnings and Precautions (5.6)]</span>.</p>
<p> The effects of other coadministered drugs on abacavir, lamivudine, or zidovudine are provided in TableÂ 4.</p>
<a name="_Refid_e7129f1f-26a5-429b-904a-fa7c9526b"></a><table>
<caption><span>Table 4. Effect of Coadministered Drugs on Abacavir, Lamivudine, and Zidovudine AUC<span class="Sup">a</span> Note: ROUTINE DOSE MODIFICATION OF ABACAVIR, LAMIVUDINE, AND ZIDOVUDINE IS NOT WARRANTED WITH COADMINISTRATION OF THE FOLLOWING DRUGS.</span></caption>
<col width="29%">
<col width="21%">
<col width="5%">
<col width="9%">
<col width="19%">
<col width="33%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="6" valign="top"><p class="First"><span class="Bold">Drugs That May Alter Lamivudine Blood Concentrations</span></p></td></tr>
<tr>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Coadministered Drug and Dose</span></p></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Lamivudine Dose</span></p></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Lamivudine Concentrations</span></p></td>
<td class="Botrule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Concentration of Coadministered Drug</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">AUC</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Variability</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Nelfinavir</p>
<p>Â Â Â 750Â mgÂ q 8Â h </p>
<p> Â Â Â x 7 to 10Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">single 150Â mg</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘10%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">95% CI:</p>
<p>1% to 20%</p>
</td>
<td class="Botrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Trimethoprim 160Â mg/</p>
<p>Sulfamethoxazole </p>
<p>Â Â Â 800Â mg daily </p>
<p> Â Â Â x 5Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">single 300Â mg</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘43%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">90% CI:</p>
<p> 32% to 55%</p>
</td>
<td class="Botrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr><td class="Botrule" align="center" colspan="6" valign="top"><p class="First"><span class="Bold">Drugs That May Alter Zidovudine Blood Concentrations</span></p></td></tr>
<tr>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Coadministered Drug and Dose</span></p></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Zidovudine Dose</span></p></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Zidovudine Concentrations</span></p></td>
<td class="Botrule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Concentration of Coadministered Drug</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">AUC</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Variability</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Atovaquone</p>
<p>Â Â Â 750Â mg q 12Â h</p>
<p>Â Â Â with food</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">200Â mg q 8Â h</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘31%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>
<p>23% to 78%<span class="Sup">b</span></p>
</td>
<td class="Botrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Clarithromycin</p>
<p>Â Â Â 500 mg twice daily</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">100 mg q 4 h x 7 days</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†“12%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Range â†“34% to â†‘14%</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">Not Reported</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Fluconazole</p>
<p>Â Â Â 400Â mg daily</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">200Â mg q 8Â h</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘74%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">95% CI:</p>
<p>54% to 98%</p>
</td>
<td class="Botrule" align="center" valign="top"><p class="First">Not Reported</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Methadone</p>
<p>Â Â Â 30 to 90Â mg daily</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">200Â mg q 4Â h</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘43%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>
<p>16% to 64%<span class="Sup">b</span></p>
</td>
<td class="Botrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Nelfinavir</p>
<p>Â Â Â 750Â mgÂ q 8Â h x 7 to</p>
<p>Â Â Â 10Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">single 200Â mg</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†“35%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>
<p> 28% to 41%</p>
</td>
<td class="Botrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Probenecid</p>
<p>Â Â Â 500 mg q 6Â h x </p>
<p>Â Â Â 2Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2Â mg/kg q 8Â h x 3Â days</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘106%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>
<p> 100% to 170%<span class="Sup">b</span></p>
</td>
<td class="Botrule" align="center" valign="top"><p class="First">Not Assessed</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Rifampin</p>
<p>Â Â Â 600 mg daily x 14 days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">200 mg q 8 h x 14 days</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†“47%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">90% CI: 41% to 53%</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">Not Assessed</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Ritonavir</p>
<p>Â Â Â 300Â mg q 6Â h x </p>
<p>Â Â Â 4 days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">200 mg q 8Â h x 4Â days</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†“25%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">95% CI:</p>
<p> 15% to 34%</p>
</td>
<td class="Botrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Valproic acid </p>
<p>Â Â Â 250Â mg or 500Â mg </p>
<p>Â Â Â q 8Â h x 4Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">100 mg q 8Â h x 4Â days</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘80%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>
<p>64% to 130%<span class="Sup">b</span></p>
</td>
<td class="Botrule" align="center" valign="top"><p class="First">Not Assessed</p></td>
</tr>
<tr><td class="Botrule" align="center" colspan="6" valign="top"><p class="First"><span class="Bold">Drugs That May Alter Abacavir Blood Concentrations</span></p></td></tr>
<tr>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Coadministered Drug and Dose</span></p></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Abacavir Dose</span></p></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Abacavir Concentrations</span></p></td>
<td class="Botrule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Concentration of Coadministered Drug</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">AUC</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Variability</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Ethanol</p>
<p>Â Â Â 0.7Â g/kg</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">single 600Â mg</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">24</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘41%</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">90% CI:</p>
<p>35% to 48%</p>
</td>
<td class="Botrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr><td colspan="6" valign="top"><p class="First">â†‘ = Increase; â†“ = Decrease; â†”Â =Â no significant change; AUC = area under the concentration versus time curve; CI = confidence interval.</p></td></tr>
<tr><td colspan="6" valign="top"><p class="First"><span class="Sup">a</span>Â <span class="Italics">See Drug Interactions (7)</span> for additional information on drug interactions.</p></td></tr>
<tr class="Last"><td class="Botrule" colspan="6" valign="top"><p class="First"><span class="Sup">b</span>Â Estimated range of percent difference.</p></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_28d5170c-0fde-4528-85e0-5851980b6c84"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Underline">Mechanism of Action:</span><span class="Italics">Abacavir:</span> Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted by cellular enzymes to the active metabolite, carbovir triphosphate (CBV-TP), an analogue of deoxyguanosine-5â€²-triphosphate (dGTP). CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. The lack of a 3â€²-OH group in the incorporated nucleotide analogue prevents the formation of the 5â€² to 3â€² phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.Â  CBV-TP is a weak inhibitor of cellular DNA polymerases Î±, Î², and Î³.</p>
<p><span class="Italics">Lamivudine:</span> Lamivudine is a synthetic nucleoside analogue. Intracellularly, lamivudine is phosphorylated to its active 5â€²-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue. 3TC-TP is a weak inhibitor of cellular DNA polymerases Î±, Î², and Î³.</p>
<p><span class="Italics">Zidovudine:</span> Zidovudine is a synthetic nucleoside analogue. Intracellularly, zidovudine is phosphorylated to its active 5â€²-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). The principal mode of action of ZDV-TP is inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue. ZDV-TP is a weak inhibitor of the cellular DNA polymerases Î± and Î³ and has been reported to be incorporated into the DNA of cells in culture.Â </p>
<p><span class="Underline">Antiviral Activity:</span><span class="Italics">Abacavir:</span> The antiviral activity of abacavir against HIV-1 was evaluated against a T-cell tropic laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> HIV-1<span class="Sub">IIIB</span> in lymphoblastic cell lines, a monocyte/macrophage tropic laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> HIV<span class="Italics">-</span>1<span class="Sub">BaL</span> in primary monocytes/macrophages, and clinical isolates in peripheral blood mononuclear cells. The concentration of drug necessary to effect viral replication by 50Â percent (EC<span class="Sub">50</span>) ranged from 3.7 to 5.8Â Î¼M (1Â Î¼MÂ =Â 0.28Â mcg/mL) and 0.07 to 1.0Â Î¼M against HIV-1<span class="Sub">IIIB</span> and HIV-1<span class="Sub">BaL</span>, respectively, and was 0.26Â Â±Â 0.18Â Î¼M against 8Â clinical isolates. The EC<span class="Sub">50</span> values of abacavir against different HIV-1 clades (A-G) ranged from 0.0015 to 1.05Â Î¼M, and against HIV-2 isolates, from 0.024 to 0.49Â Î¼M. Abacavir had synergistic activity in cell culture in combination with the NRTI zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, and the protease inhibitor (PI) amprenavir; and additive activity in combination with the NRTIs didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zalcitabine. Ribavirin (50Â Î¼M) had no effect on the antiâ€“HIV-1 activity of abacavir in cell culture.</p>
<p><span class="Italics">Lamivudine:</span> The antiviral activity of lamivudine against HIV-1 was assessed in a number of cell lines (including monocytes and fresh human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) using standard susceptibility assays. EC<span class="Sub">50</span> values (50% effective concentrations) were in the range of 0.003 to 15Â Î¼M (1Â Î¼MÂ =Â 0.23Â mcg/mL). HIV-1 from therapy-naive subjects with no amino acid substitutions associated with resistance gave median EC<span class="Sub">50</span> values of 0.429Â ÂµM (range: 0.200 to 2.007Â ÂµM) from Virco (nÂ =Â 92 baseline samples from COLA40263) and 2.35Â ÂµM (1.37 to 3.68Â ÂµM) from Monogram Biosciences (nÂ =Â 135 baseline samples from ESS30009). The EC<span class="Sub">50</span> values of lamivudine against different HIV-1 clades (A-G) ranged from 0.001 to 0.120Â ÂµM, and against HIV-2 isolates from 0.003 to 0.120Â Î¼M in peripheral blood mononuclear cells. Ribavirin (50Â Î¼M) decreased the anti-HIV-1 activity of lamivudine by 3.5-fold in MT-4 cells.</p>
<p><span class="Italics">Zidovudine:</span> The antiviral activity of zidovudine against HIV-1 was assessed in a number of cell lines (including monocytes and fresh human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>). The EC<span class="Sub">50</span> and EC<span class="Sub">90</span> values for zidovudine were 0.01 to 0.49Â ÂµM (1Â Î¼MÂ =Â 0.27Â mcg/mL) and 0.1 to 9Â Î¼M, respectively. HIV-1 from therapy-naive subjects with no amino acid substitutions associated with resistance gave median EC<span class="Sub">50</span> values of 0.011Â ÂµM (range: 0.005 to 0.110Â ÂµM) from Virco (nÂ =Â 92 baseline samples from COLA40263) and 0.0017Â ÂµM (0.006 to 0.0340Â ÂµM) from Monogram Biosciences (nÂ =Â 135 baseline samples from ESS30009). The EC<span class="Sub">50</span> values of zidovudine against different HIV-1 clades (A-G) ranged from 0.00018 to 0.02Â Î¼M, and against HIV-2 isolates from 0.00049 to 0.004Â Î¼M. In cell culture drug combination studies, zidovudine demonstrates synergistic activity with the NRTIs abacavir, didanosine, lamivudine, and zalcitabine; the NNRTIs delavirdine and nevirapine; and the PIs indinavir, nelfinavir, ritonavir, and saquinavir; and additive activity with interferon alfa. Ribavirin has been found to inhibit the phosphorylation of zidovudine in cell culture.</p>
<p><span class="Underline">Resistance:</span> HIV-1 isolates with reduced sensitivity to abacavir, lamivudine, or zidovudine have been selected in cell culture and were also obtained from subjects treated with abacavir, lamivudine, and zidovudine, or the combination of lamivudine and zidovudine.</p>
<p><span class="Italics">Abacavir:</span> Genotypic analysis of isolates selected in cell culture and recovered from abacavir-treated subjects demonstrated that amino acid substitutions K65R, L74V, Y115F, and M184V/I in HIV-1 RT contributed to abacavir resistance. In a trial of subjects receiving abacavir once or twice daily in combination with lamivudine and efavirenz once daily, 39% (7/18) of the isolates from subjects who experienced virologic failure in the abacavir once-daily arm had a &gt;2.5-fold decrease in abacavir susceptibility with a median-fold decrease of 1.3 (range: 0.5 to 11) compared with 29% (5/17) of the failure isolates in the twice-daily arm with a median-fold decrease of 0.92 (range: 0.7 to 13).</p>
<p><span class="Italics">Lamivudine:</span> Genotypic analysis of isolates selected in cell culture and recovered from lamivudine-treated subjects showed that the resistance was due to a specific amino acid substitution in the HIV-1 RT at codonÂ 184 changing the methionine to either valine or isoleucine (M184V/I).</p>
<p><span class="Italics">Zidovudine:</span> Genotypic analyses of the isolates selected in cell culture and recovered from zidovudine-treated subjects showed mutations in the HIV-1 RT gene resulting in 6Â amino acid substitutions (M41L, D67N, K70R, L210W, T215Y or F, and K219Q) that confer zidovudine resistance. In general, higher levels of resistance were associated with greater number of mutations. In some subjects harboring zidovudine-resistant virus at baseline, phenotypic sensitivity to zidovudine was restored by 12Â weeks of treatment with lamivudine and zidovudine. Combination therapy with lamivudine plus zidovudine delayed the emergence of substitutions conferring resistance to zidovudine.</p>
<p><span class="Underline">Cross-Resistance:</span> Cross-resistance has been observed among NRTIs.</p>
<p><span class="Italics">Abacavir:</span> Isolates containing abacavir resistance-associated amino acid substitutions, namely, K65R, L74V, Y115F, and M184V, exhibited cross-resistance to didanosine, emtricitabine, lamivudine, tenofovir, and zalcitabine in cell culture and in subjects. The K65R substitution can confer resistance to abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zalcitabine; the L74V substitution can confer resistance to abacavir, didanosine, and zalcitabine; and the M184V substitution can confer resistance to abacavir, didanosine, emtricitabine, lamivudine, and zalcitabine. An increasing number of thymidine analogue mutations (TAMs: M41L, D67N, K70R, L210W, T215Y/F, K219E/R/H/Q/N) is associated with a progressive reduction in abacavir susceptibility.</p>
<p><span class="Italics">Lamivudine:</span> Cross-resistance to abacavir, didanosine, tenofovir, and zalcitabine has been observed in some subjects harboring lamivudine-resistant HIV-1 isolates. In some subjects treated with zidovudine plus didanosine or zalcitabine, isolates resistant to multiple drugs, including lamivudine, have emerged (see under Zidovudine below). Cross-resistance between lamivudine and zidovudine has not been reported.</p>
<p><span class="Italics">Zidovudine:</span> In a trial of 167Â HIV-infected subjects, isolates (nÂ =Â 2) with multi-<span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine were recovered from subjects treated for â‰¥1Â year with zidovudine plus didanosine or zidovudine plus zalcitabine. The pattern of resistance-associated amino acid substitutions with such combination therapies was different (A62V, V75I, F77L, F116Y, Q151M) from the pattern with zidovudine monotherapy, with the Q151MÂ substitution being most commonly associated with multi-<span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>. The substitution at codonÂ 151 in combination with substitutions at 62, 75, 77, and 116 results in a virus with reduced susceptibility to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine. TAMs are selected by zidovudine and confer cross-resistance to abacavir, didanosine, stavudine, tenofovir, and zalcitabine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_1cc5a4c4-b94f-4ac3-9567-fbbe4e303f62"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_32c873c0-dda9-48d6-8431-be37092f3ab9"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenicity:</span></p>
<p><span class="Italics">Abacavir:</span> Abacavir was administered orally at 3Â dosage levels to separate groups of mice and rats in 2-year carcinogenicity studies. Results showed an increase in the incidence of malignant and non-<span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span>. <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">Malignant tumors</span> occurred in the preputial gland of males and the clitoral gland of females of both species, and in the liver of female rats. In addition, non-<span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span> also occurred in the liver and thyroid gland of female rats. These observations were made at systemic exposures in the range of 6 to 32 times the human exposure at the recommended dose. It is not known how predictive the results of rodent carcinogenicity studies may be for humans.</p>
<p><span class="Italics">Lamivudine:</span> Long-term carcinogenicity studies with lamivudine in mice and rats showed no evidence of carcinogenic potential at exposures up to 10Â times (mice) and 58Â times (rats) those observed in humans at the recommended therapeutic dose for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="Italics">Zidovudine:</span> ZidovudineÂ  was administered orally at 3Â dosage levels to separate groups of mice and rats (60 females and 60 males in each group). Initial single daily doses were 30, 60, and 120Â mg/kg/day in mice and 80, 220, and 600Â mg/kg/day in rats. The doses in mice were reduced to 20, 30, and 40Â mg/kg/day after dayÂ 90 because of treatment-related <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, whereas in rats only the high dose was reduced to 450Â mg/kg per day on dayÂ 91 and then to 300Â mg/kg/day on dayÂ 279.</p>
<p> In mice, 7Â late-appearing (after 19Â months) vaginal neoplasms (5Â nonmetastasizing squamous cell carcinomas, 1Â squamous cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span>, and 1Â squamous <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyp</span>) occurred in animals given the highest dose. One late-appearing squamous cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> occurred in the vagina of a middle-dose animal. No vaginal tumors were found at the lowest dose.</p>
<p> In rats, 2Â late-appearing (after 20Â months), nonmetastasizing vaginal squamous cell carcinomas occurred in animals given the highest dose. No vaginal tumors occurred at the low or middle dose in rats. No other drug-related tumors were observed in either sex of either species.</p>
<p> At doses that produced tumors in mice and rats, the estimated drug exposure (as measured by AUC) was approximately 3Â times (mouse) and 24Â times (rat) the estimated human exposure at the recommended therapeutic dose of 100Â mg every 4Â hours.</p>
<p> Two transplacental carcinogenicity studies were conducted in mice. One study administered zidovudine at doses of 20Â mg/kg/day or 40Â mg/kg/day from gestation dayÂ 10 through parturition and lactation with dosing continuing in offspring for 24Â months postnatally. At these doses, exposures were approximately 3Â times the estimated human exposure at the recommended doses. After 24Â months at the 40-mg/kg/day dose, an increase in incidence of vaginal tumors was noted with no increase in tumors in the liver or lung or any other organ in either gender. These findings are consistent with results of the standard oral carcinogenicity study in mice, as described earlier. A second study administered zidovudine at maximum tolerated doses of 12.5Â mg/day or 25Â mg/day (~1,000Â mg/kg nonpregnant body weight or ~450Â mg/kg of term body weight) to pregnant mice from daysÂ 12 through 18 of gestation. There was an increase in the number of tumors in the lung, liver, and female reproductive tracts in the offspring of mice receiving the higher dose level of zidovudine.</p>
<p> It is not known how predictive the results of rodent carcinogenicity studies may be for humans.</p>
<p><span class="Underline">Mutagenicity:</span></p>
<p><span class="Italics">Abacavir:</span> Abacavir induced chromosomal aberrations both in the presence and absence of metabolic activation in an inÂ vitro cytogenetic study in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Abacavir was mutagenic in the absence of metabolic activation, although it was not mutagenic in the presence of metabolic activation in an L5178Y/TK+/- mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay. Abacavir was clastogenic in males and not clastogenic in females in an inÂ vivo mouse bone marrow micronucleus assay. Abacavir was not mutagenic in bacterial mutagenicity assays in the presence and absence of metabolic activation.</p>
<p><span class="Italics">Lamivudine:</span> Lamivudine was mutagenic in an L5178Y/TK+/- mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay and clastogenic in a cytogenetic assay using cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Lamivudine was negative in a microbial mutagenicity assay, in an inÂ vitro cell transformation assay, in a rat micronucleus test, in a rat bone marrow cytogenetic assay, and in an assay for unscheduled DNA synthesis in rat liver.</p>
<p><span class="Italics">Zidovudine:</span> Zidovudine was mutagenic in an L5178Y/TK+/- mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, positive in an inÂ vitro cell transformation assay, clastogenic in a cytogenetic assay using cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and positive in mouse and rat micronucleus tests after repeated doses. It was negative in a cytogenetic study in rats given a single dose.</p>
<p><span class="Underline">Impairment of Fertility:</span></p>
<p><span class="Italics">Abacavir:</span> Abacavir had no adverse effects on the mating performance or fertility of male and female rats at a dose approximately 8Â times the human exposure at the recommended dose based on body surface area comparisons.</p>
<p><span class="Italics">Lamivudine:</span> In a study of reproductive performance, lamivudine, administered to male and female rats at doses up to 130Â times the usual adult dose based on body surface area considerations, revealed no evidence of impaired fertility judged by conception rates and no effect on the survival, growth, and development to weaning of the offspring.</p>
<p><span class="Italics">Zidovudine:</span> Zidovudine, administered to male and female rats at doses up to 7Â times the usual adult dose based on body surface area considerations, had no effect on fertility judged by conception rates.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_377428a3-9508-4018-8fc9-55c6ad7f53ab"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Myocardial degeneration</span> was found in mice and rats following administration of abacavir for 2Â years. The systemic exposures were equivalent to 7 to 24Â times the expected systemic exposure in humans. The clinical relevance of this finding has not been determined.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_8479d1bc-aa07-4e5b-b2cd-698f57bbb276"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The following trial was conducted with the individual components of TRIZIVIR <span class="Italics">[see Clinical Pharmacology (12.3)].</span></p>
<p><span class="Bold">CNA3005</span> was a multicenter, double-blind, controlled trial in which 562Â HIV-1-infected, therapy-naive adults were randomized to receive either ZIAGEN (300Â mg twice daily) plus COMBIVIR (lamivudine 150Â mg/zidovudine 300Â mg twice daily), or indinavir (800Â mg 3Â times a day) plus COMBIVIR twice daily. The trial was stratified at randomization by pre-entry plasma HIV-1 RNA 10,000 to 100,000Â copies/mL and plasma HIV-1 RNA &gt;100,000Â copies/mL. Trial participants were male (87%), Caucasian (73%), black (15%), and Hispanic (9%). At baseline the median age was 36Â years, the median pretreatment CD4+Â cell count was 360Â cells/mm<span class="Sup">3</span>, and median plasma HIV-1 RNA was 4.8Â log<span class="Sub">10</span>Â copies/mL. Proportions of subjects with plasma HIV-1 RNA &lt;400Â copies/mL (using Roche AMPLICOR HIV-1 MONITOR<span class="Sup">Â®</span> Test) through 48Â weeks of treatment are summarized in Table 5.</p>
<a name="_Refid_3a1dcce2-79e1-4f1e-a240-c035f3b3e"></a><table>
<caption><span>Table 5. Outcomes of Randomized Treatment Through Week 48 (CNA3005)</span></caption>
<col width="49%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Outcome</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First">ZIAGEN plus</p>
<p>Lamivudine/Zidovudine</p>
<p>(nÂ =Â 262)</p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First">Indinavir plus</p>
<p>Lamivudine/Zidovudine</p>
<p>(nÂ =Â 265)</p>
</td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Responder<span class="Sup">a</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">49%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">50%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Virologic failure<span class="Sup">b</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">31%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">28%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Discontinued due to adverse reactions</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">10%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">12%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Discontinued due to other reasons<span class="Sup">c</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">10%</p></td>
</tr>
<tr><td class="Lrule Rrule" colspan="3" valign="top"><p class="First"><span class="Sup">a</span>Â Patients achieved and maintained confirmed HIV-1 RNA &lt;400Â copies/mL.</p></td></tr>
<tr><td class="Lrule Rrule" colspan="3" valign="top"><p class="First"><span class="Sup">b</span>Â Includes viral rebound and failure to achieve confirmed &lt;400Â copies/mL by Week 48.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="3" valign="top"><p class="First"><span class="Sup">c</span>Â Includes consent withdrawn, lost to follow-up, protocol violations, those with missing data, clinical progression, and other.</p></td></tr>
</tbody>
</table>
<p>Treatment response by plasma HIV-1 RNA strata is shown in TableÂ 6.</p>
<a name="_Refid_81533d37-6ed7-4302-a253-f1965b1f6"></a><table>
<caption><span>TableÂ 6. Proportions of Responders Through Week 48 By Screening Plasma HIV-1 RNA Levels (CNA3005)</span></caption>
<col width="21%">
<col width="19%">
<col width="6%">
<col width="19%">
<col width="6%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">
<p class="First">Screening </p>
<p>HIV-1 RNA</p>
<p>(copies/mL)</p>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First">ZIAGEN plus</p>
<p>Lamivudine/Zidovudine</p>
<p>(nÂ =Â 262)</p>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First">Indinavir plus </p>
<p>Lamivudine/Zidovudine</p>
<p>(nÂ =Â 265)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt;400Â copies/mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">n</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">&lt;400Â copies/mL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">N</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">â‰¥10,000 - â‰¤100,000</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">50%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">166</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">48%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">165</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">&gt;100,000</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">48%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">96</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">52%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">100</p></td>
</tr>
</tbody>
</table>
<p>In subjects with baseline viral load &gt;100,000Â copies/mL, percentages of subjects with HIV-1 RNA levels &lt;50Â copies/mL were 31% in the group receiving abacavir vs. 45% in the group receiving indinavir.</p>
<p> Through WeekÂ 48, an overall mean increase in CD4+ cell count of about 150Â cells/mm<span class="Sup">3</span> was observed in both treatment arms. Through Week 48, 9Â subjects (3.4%) in the group receiving abacavir sulfate (6Â CDC classification C events and 3Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>) and 3Â subjects (1.5%) in the group receiving indinavir (2Â CDC classification C events and 1Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) experienced clinical disease progression.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_61aa0f76-0e66-48d0-a89e-7c94b1f0045d"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. <span class="Italics">Lancet</span>. 2008;371 (9622):1417-1426.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_529aa072-6377-4d35-9b34-1436f275dddc"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">TRIZIVIR is available as tablets. Each tablet contains 300Â mg of abacavir as abacavir sulfate, 150Â mg of lamivudine, and 300Â mg of zidovudine. The tablets are blue-green capsule-shaped, film-coated, and imprinted with GX LL1 on one side with no markings on the reverse side.</p>
<p>They are supplied by <span class="Bold"> State of Florida DOH Central Pharmacy</span> as follows:</p>
<table width="100%">
<colgroup>
<col width="13%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="12%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<td align="center"><span class="Bold">NDC</span></td>
<td align="center"><span class="Bold">Strength</span></td>
<td align="center"><span class="Bold">Quantity/Form</span></td>
<td align="center"><span class="Bold">Color</span></td>
<td align="center"><span class="Bold">Source Prod. Code</span></td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">53808-0990-1</td>
<td align="center">300 mg / 150 mg / 300 mg</td>
<td align="center">30 Tablets in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</td>
<td align="center">blue-green</td>
<td align="center">49702-217</td>
</tr></tbody>
</table>
<p><span class="Bold">Store at 25Â°C (77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) (see USP Controlled Room Temperature).</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_79893717-1044-4325-a067-3240b75566e7"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"> See FDA-approved patient labeling (Medication Guide)</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span>:</span> Inform patients:</p>
<dl>
<dt>â€¢</dt>
<dd>that a Medication Guide and Warning Card summarizing the symptoms of the abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> and other product information will be dispensed by the pharmacist with each new prescription and refill of TRIZIVIR, and encourage the patient to read the Medication Guide and Warning Card every time to obtain any new information that may be present about TRIZIVIR. (The complete text of the Medication Guide is reprinted at the end of this document.)</dd>
<dt>â€¢</dt>
<dd>to carry the Warning Card with them.</dd>
<dt>â€¢</dt>
<dd>how to identify a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span><span class="Italics">[see Warnings and Precautions (5.1), Medication Guide]</span>.</dd>
<dt>â€¢</dt>
<dd>that if they develop symptoms consistent with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> they should call their doctor right away to determine if they should stop taking TRIZIVIR.</dd>
<dt>â€¢</dt>
<dd>that a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> can worsen and lead to hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if TRIZIVIR is not immediately discontinued.</dd>
<dt>â€¢</dt>
<dd>to not restart TRIZIVIR or any other abacavir-containing product following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> because more severe symptoms can occur within hours and may include life-threatening <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</dd>
<dt>â€¢</dt>
<dd>that a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is usually reversible if it is detected promptly and TRIZIVIR is stopped right away.</dd>
<dt>â€¢</dt>
<dd>that if they have interrupted TRIZIVIR for reasons other than symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (for example, those who have an interruption in drug supply), a serious or fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> may occur with reintroduction of abacavir.</dd>
<dt>â€¢</dt>
<dd>to not restart TRIZIVIR or any other abacavir-containing product without medical consultation and that restarting abacavir needs to be undertaken only if medical care can be readily accessed by the patient or others.</dd>
<dt>â€¢</dt>
<dd>TRIZIVIR should not be coadministered with ATRIPLA, COMBIVIR, COMPLERA, EMTRIVA, EPIVIR, EPIVIR-HBV, EPZICOM, RETROVIR (zidovudine), TRUVADA, or ZIAGEN.</dd>
</dl>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>:</span> Patients should be informed that the important toxicities associated with zidovudine are <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and/or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. They should be told of the extreme importance of having their blood counts followed closely while on therapy, especially for patients with advanced HIV-1 disease <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span></span>: Patients should be informed that <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span> with pathological changes, similar to that produced by HIV-1 disease, have been associated with prolonged use of zidovudine <span class="Italics">[see Warnings and Precautions (5.3)]</span>.Â  </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span>:</span> Inform patients that some HIV medicines, including TRIZIVIR, can cause a rare, but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) <span class="Italics">[see Warnings and Precautions (5.4)]</span>.Â  </p>
<p><span class="Underline">HIV-1/ HBV Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span> Patients co-infected with HIV-1 and HBV should be informed that deterioration of liver disease has occurred in some cases when treatment with lamivudine was discontinued. Patients should be advised to discuss any changes in regimen with their physician <span class="Italics">[see Warnings and Precautions (5.5)]</span>.Â  </p>
<p><span class="Underline">HIV-1/HCV Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span> Patients with HIV-1/HCV co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be informed that hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin <span class="Italics">[see Warnings and Precautions (5.6)]</span>.Â  </p>
<p><span class="Underline">Redistribution/Accumulation of Body Fat:</span> Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time <span class="Italics">[see Warnings and Precautions (5.8)]</span>.Â  </p>
<p><span class="Underline">Information About HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span> TRIZIVIR is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and patients may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients should remain under the care of a physician when using TRIZIVIR. </p>
<p> Patients should be advised to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Do not share needles or other injection equipment.</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood. </dd>
<dt>â€¢</dt>
<dd><span class="Bold">Do not breastfeed. Lamivudine and zidovudine are excreted in human breast milk. It is not known if abacavir can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk. </span></dd>
</dl>
<p> Patients should be informed to take all HIV medications exactly as prescribed. </p>
<p>COMBIVIR, EPIVIR, EPZICOM, RETROVIR, TRIZIVIR, and ZIAGEN are registered trademarks of ViiV Healthcare.</p>
<p>Other brands are trademarks of their respective owners and are not trademarks of ViiV Healthcare. The makers of these brands are not affiliated with and do not endorse ViiV Healthcare or its products.</p>
<p>Manufactured for:</p>
<p>ViiV Healthcare</p>
<p>Research Triangle Park, NC 27709</p>
<p>by:</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Lamivudine is manufactured under agreement from</p>
<p><span class="Bold">Shire Pharmaceuticals Group plc</span></p>
<p>Basingstoke, UK</p>
<p>Â©2013, ViiV Healthcare. All rights reserved.</p>
<p>This Product was Repackaged By:</p>
<p><span class="Bold">State of Florida DOH Central Pharmacy</span><br> 104-2 Hamilton Park Drive<br> Tallahassee, FL 32304<br> United States<br></p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_71141da5-b281-4613-b976-e9074e8dfe7a"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">TRIZIVIR<span class="Sup">Â®</span> (TRY-zih-veer)</span></p>
<p>(abacavir sulfate, lamivudine, and zidovudine</p>
<p><span class="Bold">Tablets</span></p>
<p>Read this Medication Guide before you start taking TRIZIVIR and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. Be sure to carry your TRIZIVIR Warning Card with you at all times.</p>
<p><span class="Bold">What is the most important information I should know about TRIZIVIR?</span></p>
<p><span class="Bold">1.Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>).</span> TRIZIVIR contains abacavir (also contained in ZIAGEN<span class="Sup">Â®</span> and EPZICOM<span class="Sup">Â®</span>). Patients taking TRIZIVIR may have a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>) that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Your risk of this <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> is much higher if you have a gene variation called HLA-B*5701. Your healthcare provider can determine with a blood test if you have this gene variation.</p>
<p><span class="Bold">If you get a symptom from 2 or more of the following groups while taking TRIZIVIR, call your healthcare provider right away to find out if you should stop taking TRIZIVIR.</span></p>
<table>
<col width="11%">
<col width="61%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Symptom(s)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Group 1</span></p></td>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Group 2</span></p></td>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Group 3</span></p></td>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, abdominal (stomach area) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Group 4</span></p></td>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Generally ill feeling, extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, or achiness</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Group 5</span></p></td>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> </span></p></td>
</tr>
</tbody>
</table>
<p>A list of these symptoms is on the Warning Card your pharmacist gives you. <span class="Bold">Carry this Warning Card with you at all times.</span></p>
<p><span class="Bold">If you stop TRIZIVIR because of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, never take TRIZIVIR(abacavir sulfate, lamivudine, and zidovudine)or any other abacavir-containing medicine (ZIAGEN and EPZICOM) again</span>. If you take TRIZIVIR or any other abacavir-containing medicine again after you have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="Bold">within hours</span> you may get <span class="Bold">life-threatening symptoms</span> that may include <span class="Bold">very <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> </span>or<span class="Bold"> <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span>If you stop TRIZIVIR, for any other reason, even for a few days, and you are not allergic to TRIZIVIR, talk with your healthcare provider before taking it again. Taking TRIZIVIR again can cause a serious allergic or life-threatening reaction, even if you never had anÂ  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to it before.</p>
<p><span class="Bold">If your healthcare provider tells you that you can take TRIZIVIR again, start taking it when you are around medical help or people who can call a healthcare provider if you need one.</span></p>
<p><span class="Bold">2. Blood problems. </span>RETROVIR<span class="Sup">Â®</span>, one of the medicines in TRIZIVIR, can cause serious blood cell problems. These include reduced numbers of white blood cells (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>) and extremely reduced numbers of red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>). These blood cell problems are especially likely to happen in patients with advanced human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV) disease or AIDS. Your doctor should be checking your blood cell counts regularly while you are taking TRIZIVIR. This is especially important if you have advanced HIV or AIDS. This is to make sure that any blood cell problems are found quickly.</p>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> (buildup of acid in the blood). Some human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV) medicines, including TRIZIVIR, can cause a rare but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a serious medical emergency that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and must be treated in the hospital. </span></p>
<p><span class="Bold">Call your healthcare provider right away if you get any of the following signs or symptoms of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>: </span></p>
<dl>
<dt>â€¢</dt>
<dd>you feel very weak or tired</dd>
<dt>â€¢</dt>
<dd>you have unusual (not normal) <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span></dd>
<dt>â€¢</dt>
<dd>you have trouble breathing</dd>
<dt>â€¢</dt>
<dd>you have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>â€¢</dt>
<dd>you feel <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, especially in your arms and legs</dd>
<dt>â€¢</dt>
<dd>you feel dizzy or light-headed</dd>
<dt>â€¢</dt>
<dd>you have a fast or irregular heartbeat</dd>
</dl>
<p><span class="Bold">4. Serious liver problems. Some people who have taken medicines like TRIZIVIR have developed serious liver problems called hepatotoxicity, with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) and fat in the liver (steatosis). <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with steatosis is a serious medical emergency that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
<p><span class="Bold">Call your healthcare provider right away if you get any of the following signs or symptoms of liver problems:</span></p>
<dl>
<dt>â€¢</dt>
<dd>your skin or the white part of your eyes turns yellow (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</dd>
<dt>â€¢</dt>
<dd>your urine turns dark </dd>
<dt>â€¢</dt>
<dd>your bowel movements (stools) turn light in color</dd>
<dt>â€¢</dt>
<dd>you donâ€™t feel like eating food for several days or longer</dd>
<dt>â€¢</dt>
<dd>you feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>)</dd>
<dt>â€¢</dt>
<dd>you have lower stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
</dl>
<p><span class="Bold">You may be more likely to get <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or serious liver problems if you are female, very overweight, or have been taking nucleoside analogue medicines for a long time.</span></p>
<p><span class="Bold">5. Use with interferon and ribavirin-based regimens.</span> Worsening of liver disease (sometimes resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) has occurred in patients infected with both HIV and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus who are taking anti-HIV medicines and are also being treated for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C with interferon with or without ribavirin. If you are taking TRIZIVIR as well as interferon with or without ribavirin and you experience side effects, be sure to tell your healthcare provider.</p>
<p><span class="Bold">6. If you have HIV and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, your <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may get worse if you stop taking TRIZIVIR.</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take TRIZIVIR exactly as prescribed.</dd>
<dt>â€¢</dt>
<dd>Do not run out of TRIZIVIR.</dd>
<dt>â€¢</dt>
<dd>Do not stop TRIZIVIR without talking to your healthcare provider.</dd>
</dl>
<p>Your healthcare provider should monitor your health and do regular blood tests to check your liver if you stop taking TRIZIVIR.</p>
<p><span class="Bold">7. <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span> (<span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>). RETROVIR, one of the medicines in TRIZIVIR, can cause <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>. This can be a serious problem.</span></p>
<p><span class="Bold">What is TRIZIVIR?</span></p>
<p>TRIZIVIR is a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. TRIZIVIR contains 3Â medicines: abacavir (ZIAGEN), lamivudine or 3TC (EPIVIR<span class="Sup">Â®</span>), and zidovudine, AZT, or ZDV (RETROVIR). All 3 of these medicines are called nucleoside analogue reverse transcriptase inhibitors (NRTIs). When used together, they help lower the amount of HIV in your blood.</p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">TRIZIVIR does not cure <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> or AIDS.</span></dd>
<dt>â€¢</dt>
<dd>It is not known if TRIZIVIR will help you live longer or have fewer of the medical problems that people get with HIV or AIDS. </dd>
<dt>â€¢</dt>
<dd>It is very important that you see your healthcare provider regularly while you are taking TRIZIVIR.</dd>
</dl>
<p><span class="Bold">Who should not take TRIZIVIR?</span></p>
<p><span class="Bold">Do not take TRIZIVIR if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">are allergic to abacavir or any of the ingredients in TRIZIVIR. See the end of this Medication Guide for a complete list of ingredients in TRIZIVIR.</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">have certain liver problems.</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">are an adolescent who weighs less than 90 pounds.</span></dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking TRIZIVIR?</span></p>
<p><span class="Bold">Before you take TRIZIVIR, tell your healthcare provider if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">have been tested and know whether or not you have a particular gene variation called HLA-B*5701.</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">have <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or have other liver problems.</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">have kidney problems.</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">have low blood cell counts (bone marrow problem). </span>Ask your doctor if you are not sure.</dd>
<dt>â€¢</dt>
<dd><span class="Bold">have heart problems, smoke, or have diseases that increase your risk of heart disease such as high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">are pregnant or plan to become pregnant.</span> It is not known if TRIZIVIR will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.</dd>
</dl>
<p><span class="Bold">Pregnancy Registry.</span> If you take TRIZIVIR while you are pregnant, talk to your healthcare provider about how you can take part in the Pregnancy Registry for TRIZIVIR. The purpose of the pregnancy registry is to collect information about the health of you and your baby.</p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">are breastfeeding or plan to breastfeed. Do not breastfeed</span>. Lamivudine and zidovudine are excreted in human breast milk. We do not know if abacavir can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and nonprescription medicines, vitamins, and herbal supplements.</p>
<p><span class="Bold">Especially tell your healthcare provider if you take:</span></p>
<dl>
<dt>â€¢</dt>
<dd>alcohol</dd>
<dt>â€¢</dt>
<dd>medicines used to treat <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> viruses such as interferon or ribavirin</dd>
<dt>â€¢</dt>
<dd>methadone</dd>
<dt>â€¢</dt>
<dd>BACTRIM<span class="Sup">Â®</span>, SEPTRA<span class="Sup">Â®</span> (trimethoprim [TMP/sulfamethoxazole SMX])</dd>
<dt>â€¢</dt>
<dd>CYTOVENE<span class="Sup">Â®</span>, DHPG (ganciclovir)</dd>
<dt>â€¢</dt>
<dd>interferon-alfa</dd>
<dt>â€¢</dt>
<dd>ADRIAMYCIN<span class="Sup">Â®</span> (doxorubicin)</dd>
<dt>â€¢</dt>
<dd>COPEGUS<span class="Sup">Â®</span>, REBETOL<span class="Sup">Â®</span>, VIRAZOLE<span class="Sup">Â®</span> (ribavirin)</dd>
<dt>â€¢</dt>
<dd>any bone marrow suppressive medicines or cytotoxic medicines. Ask your doctor if you are not sure.</dd>
<dt>â€¢</dt>
<dd>ATRIPLA<span class="Sup">Â®</span> (efavirenz/emtricitabine/tenofovir disoproxil fumarate)</dd>
<dt>â€¢</dt>
<dd>COMBIVIR<span class="Sup">Â®</span> (lamivudine and zidovudine)</dd>
<dt>â€¢</dt>
<dd>COMPLERA<span class="Sup">Â®</span> (emtricitabine/rilpivirine/tenofovir disoproxil fumarate)</dd>
<dt>â€¢</dt>
<dd>EMTRIVA<span class="Sup">Â®</span> (emtricitabine)</dd>
<dt>â€¢</dt>
<dd>EPIVIR or EPIVIR-HBV<span class="Sup">Â®</span> (lamivudine)</dd>
<dt>â€¢</dt>
<dd>EPZICOM (abacavir sulfate and lamivudine)</dd>
<dt>â€¢</dt>
<dd>RETROVIR (zidovudine)</dd>
<dt>â€¢</dt>
<dd>TRUVADA<span class="Sup">Â®</span> (emtricitabine/tenofovir disoproxil fumarate)</dd>
<dt>â€¢</dt>
<dd>ZERIT<span class="Sup">Â®</span> (stavudine)</dd>
<dt>â€¢</dt>
<dd>ZIAGEN (abacavir sulfate)</dd>
</dl>
<p>Ask your healthcare provider if you are not sure if you take one of the medicines listed above.</p>
<p>TRIZIVIR may affect the way other medicines work, and other medicines may affect how TRIZIVIR works.</p>
<p>Know the medicines you take. Keep a list of your medicines with you to show to your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take TRIZIVIR?</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Take TRIZIVIR exactly as your healthcare provider tells you to take it.</span></dd>
<dt>â€¢</dt>
<dd>TRIZIVIR may be taken with or without food.</dd>
<dt>â€¢</dt>
<dd>Do not skip doses.</dd>
<dt>â€¢</dt>
<dd><span class="Bold">Do not let your TRIZIVIR run out.</span></dd>
</dl>
<p>If you stop your anti-HIV medicines, even for a short time, the amount of virus in your blood may increase and the virus may become harder to treat.If you take too much TRIZIVIR, call your healthcare provider or poison control center or go to the nearest hospital emergency room right away.</p>
<p><span class="Bold">What are the possible side effects of TRIZIVIR?</span></p>
<p><span class="Bold">TRIZIVIR can cause serious side effects including <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, and liver problems. See â€œWhat is the most important information I should know about TRIZIVIR?â€?</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Blood problems.</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span>.</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Changes in immune system (<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span>).</span> Your immune system may get stronger and begin to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that have been hidden in your body for a long time. Tell your healthcare provider if you start having new or worse symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> after you start taking TRIZIVIR.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Changes in body fat (fat redistribution).</span> Changes in body fat (<span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span> or <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>) can happen in some people taking antiretroviral medicines including TRIZIVIR.</dd>
<dt>Â </dt>
<dd>These changes may include:</dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>more fat in or around your trunk, upper back and neck (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), breast or chest</dd>
<dt>â€¢</dt>
<dd>loss of fat in your legs, arms, or face</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>). </span>Some HIV medicines including TRIZIVIR may increase your risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</dd>
</dl>
<p><span class="Bold">The most common side effects of TRIZIVIR include:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and/or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></dd>
<dt>â€¢</dt>
<dd>muscle and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span></dd>
<dt>â€¢</dt>
<dd>ear, nose, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">cold symptoms</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span></dd>
</dl>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of TRIZIVIR. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store TRIZIVIR?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store TRIZIVIR at 59Â°F to 86Â°F (15Â°C to 30Â°C).</dd>
<dt>â€¢</dt>
<dd><span class="Bold">Keep TRIZIVIR and all medicines out of the reach of children.</span></dd>
</dl>
<p><span class="Bold">General information for safe and effective use of TRIZIVIR.</span></p>
<p>Avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Do not share needles or other injection equipment.</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood. </dd>
</dl>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TRIZIVIR for a condition for which it was not prescribed. Do not give TRIZIVIR to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about TRIZIVIR. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for the information about TRIZIVIR that is written for healthcare professionals.</p>
<p>For more information go to <a href="#_Ref">www.TRIZIVIR.com</a> or call 1-877-844-8872.</p>
<p><span class="Bold">What are the ingredients in TRIZIVIR?</span></p>
<p>Active ingredients: abacavir sulfate, lamivudine, and zidovudine</p>
<p>Inactive ingredients: magnesium stearate, microcrystalline cellulose, sodium starch glycolate, and OPADRY<span class="Sup">Â®</span> green 03B11434, a film coating made of FD&amp;C Blue No. 2, hypromellose, polyethylene glycol, titanium dioxide, and yellow iron oxide.</p>
<p>This Medication Guide has been approved by the US Food and Drug Administration.</p>
<p>COMBIVIR, EPIVIR, EPZICOM, RETROVIR, TRIZIVIR, and ZIAGEN are registered trademarks of ViiV Healthcare.</p>
<p>The brands listed are trademarks of their respective owners and are not trademarks of ViiV Healthcare. The makers of these brands are not affiliated with and do not endorse ViiV Healthcare or its products.</p>
<p>Manufactured for:</p>
<p>ViiV Healthcare</p>
<p>Research Triangle Park, NC 27709</p>
<p>by:</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Lamivudine is manufactured under agreement from</p>
<p><span class="Bold">Shire Pharmaceuticals Group plc</span></p>
<p>Basingstoke, UK</p>
<p>Â©2013, ViiV Healthcare. All rights reserved.</p>
<p>This Product was Repackaged By:</p>
<p><span class="Bold">State of Florida DOH Central Pharmacy</span><br> 104-2 Hamilton Park Drive<br> Tallahassee, FL 32304<br> United States<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_51db1c2e-1d85-428f-a177-b5f44c8c0252"></a><a name="section-18"></a><p></p>
<h1>PACKAGE LABEL</h1>
<p class="First">Label Image for <span class="Bold">53808-0990<br>300mg  /  150mg  /  300mg</span></p>
<p><img alt="Label Image for 300mg  /  150mg  /  300mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3354e50f-4dc5-413f-b5ae-87353ab8913d&amp;name=Trizivir%20300-150mg.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRIZIVIRÂ 		
					</strong><br><span class="contentTableReg">abacavir sulfate, lamivudine, and zidovudine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53808-0990(NDC:49702-217)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ABACAVIR SULFATE</strong> (ABACAVIR) </td>
<td class="formItem">ABACAVIR</td>
<td class="formItem">300Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>LAMIVUDINE</strong> (LAMIVUDINE) </td>
<td class="formItem">LAMIVUDINE</td>
<td class="formItem">150Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZIDOVUDINE</strong> (ZIDOVUDINE) </td>
<td class="formItem">ZIDOVUDINE</td>
<td class="formItem">300Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (blue-green) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">21mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GX;LL1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53808-0990-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021205</td>
<td class="formItem">02/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>State of Florida DOH Central Pharmacy
							(829348114)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">State of Florida DOH Central Pharmacy</td>
<td class="formItem"></td>
<td class="formItem">829348114</td>
<td class="formItem">repack(53808-0990)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a6299f1c-1ddb-4da4-a38d-2cb34eca0c02</div>
<div>Set id: 3354e50f-4dc5-413f-b5ae-87353ab8913d</div>
<div>Version: 2</div>
<div>Effective Time: 20140424</div>
</div>
</div>Â <div class="DistributorName">State of Florida DOH Central Pharmacy</div></p>
</body></html>
